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ABSTRACT 
Platelets are crucial to the hemostatic response.  Their role in coagulation is well 
documented and they have been considered for some time to promote resistance of 
thrombi to fibrinolysis.  Platelets confer resistance to lysis by promoting clot retraction of 
the immediate fibrin network and through release of PAI-1 from their -granules.  However, 
recent developments in the field now indicate that the role of platelets in fibrinolysis is 
much more diverse.  Indeed, recent studies of different subpopulations of platelets that 
develop upon activation suggest that platelets can play varied roles in regulating 
hemostasis.  Likewise the developments in our understanding of thrombus formation, 
architecture and changes in fibrin deposition and composition suggest that these different 
subpopulations of platelets may populate distinct areas within thrombi and potentially 
dictate the local hemostatic balance in these areas.  This review will discuss the diverse roles 
of platelets in fibrinolysis and highlight the recent developments in the field and the 
contribution of both the intracellular pool of modulators as well as the membrane surface in 
regulating these processes.          
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INTRODUCTION 
Platelets are at the nucleus of hemostasis, serving a multitude of functions to arrest 
bleeding and facilitate wound healing. Their vital role is evidenced by the fact that 
transfusion of platelets can dramatically restore hemostatic competency with higher 
platelet counts, correlating directly with an improvement in clinical bleeding. Interaction of 
platelets with the exposed components of the vessel wall post-injury generates the initial 
plug to limit blood loss.  When platelets bind these matrix proteins they undergo rapid 
activation to release a host of clotting factors into the surrounding milieu. In addition, they 
change both the shape and composition of their membrane, allowing direct interaction with 
coagulation proteins. Platelets are a focal point for thrombin generation, interact directly 
with circulating fibrinogen facilitating generation of insoluble fibrin and act as an anchor for 
the growing scaffold of the clot. The crucial requirement of platelets for hemostasis is 
mirrored in the disease state of thrombosis where aberrant platelet function significantly 
augments thrombus formation with deleterious consequences. As a result, multiple 
antiplatelet agents are now used clinically to restrain the ability of platelets to participate in 
uncontrolled thrombus formation.1 Interestingly, in addition to their fundamental role of 
platelets in clot formation, they contain a host of fibrinolytic factors that regulate 
fibrinolysis. Until recently that role has been presumed to be antifibrinolytic due to the high 
concentrations of fibrinolytic inhibitors, contained within platelets.2-4 More recently 
additional profibrinolytic functions of platelets have been described which indicate that 
these unique anucleate cells may mediate fibrin dissolution as well as their established role 
in fibrin formation.5,6 This review will focus on the different means by which platelets can 
participate in the mechanisms that regulate fibrinolysis and recent work by our laboratory 
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and others which suggest that platelets are central to regulation of both sides of the 
fibrinolytic process.   
 
Crosstalk between fibrinolysis and clot retraction 
The susceptibility of the fibrin network to lysis is dictated by its structure.7 Platelets actively 
compress and reduce clot volume via a process termed retraction thereby consolidating the 
integrity of the hemostatic plug.8 During clot retraction the fibrin network around the 
wound site is tightened via interactions with the integrin IIb3, previously termed platelet 
glycoprotein IIb/IIIa. Upon platelet activation, IIb3 undergoes a conformational change 
and binds extracellular fibrinogen9 which initiates IIb3-mediated outside-in signalling.10 
IIb3 is connected to the intracellular actin cytoskeleton via talin11 (Figure 1), allowing it to 
exert a contractile force on extracellular fibrin fibers. Platelet factor XIII-A (FXIII-A) 
modulates reorganization of the activated platelet cytoskeleton and IIbβ3 within 
sphingomyelin-rich lipid rafts, indicating that fibrin-IIbβ3-myosin act as an axis to support 
clot retraction. 12  
 
Retracted clots are resistant to fibrinolytic degradation13 and lyse more slowly than non-
retracted clots14 due to condensing of cross-linked alpha-2 antiplasmin (2AP)15 and 
reduced binding of tissue plasminogen activator (tPA) to fibrin.16 In platelet-rich clots the 
availability of plasminogen and plasminogen activators is reduced by clot retraction due to 
extrusion of these proteins. These studies indicate the integral role of platelets in clot 
retraction and how this impacts progression of fibrinolysis.   

-GRANULE PROTEINS 
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There are three types of secretory granules, namely the -granules, dense granules and 
lysosomes (Figure 1).  -granules are the most abundant with around 50-80 per cell 
accounting for 10% of the platelet volume, in contrast dense granules comprise only 1%.17  
Upon activation platelets release more than 300 proteins the majority of these arising from 
-granules.  -granule content is derived by several mechanisms including biosynthesis 
within their precursor cells  megakaryocytes18-20, endocytosis21,22, and pinocytosis,23 at both 
the megakaryocyte and platelet level.   
 
Differential packaging of -granule proteins including von Willebrand factor (VWF), 
fibrinogen, vascular endothelial growth factor, endostatin, thrombospondin-1, and basic 
fibroblast growth factor from specific -granule subpopulations has been reported.24,25  
More intriguingly pro- and anti- angiogenic proteins were observed in distinct -granule 
populations and were differentially released.25  Indeed, a similar mechanism for storage and 
release of pro- and anti- fibrinolytic proteins may potentially exist and warrants further 
investigation.  In the remainder of this section we describe fibrinolytic proteins that are both 
endocytosed and biosynthesized within platelets and their contribution to fibrinolysis (Table 
1).  
 
Fibrinogen 
Platelets have a pool of fibrinogen which is endocytosed from plasma into platelets and 
megakaryocytes26  and stored within -granules and the cytoplasm.  Platelet fibrinogen 
accounts for 3-10%27,28 of total platelet protein (5-25 mg/1011 platelets) with approximately 
25%27 being found in -granules29,30.  The integrin IIb3 is involved in endocytosis of 
fibrinogen, as patients with Type 1 Glanzmann thrombasthenia (who exhibit defective copy 
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numbers of IIb3) have significantly reduced levels of fibrinogen within their platelets.31-33  
In megakaryocytes, fibrinogen is endocytosed and trafficked to multivesicular bodies, which 
are precursors to mature -granules.34  There are potentially other receptors involved in the 
endocytosis of fibrinogen, such as the integrin Vβ3, which may facilitate binding of soluble 
fibrinogen to the inactive conformation of IIb3, thereby enhancing uptake of fibrinogen.35  
Consistent with this hypothesis, deficiency of both Vβ3 and IIb3 further attenuates 
fibrinogen accumulation in platelets.36  Further work is required to define the receptors 
involved in the uptake of fibrinogen and its relative distribution within quiescent platelets.  
Both the cytosolic and -granule pools of fibrinogen are released in response to platelet 
stimulation29,30 and is partially retained on the activated membrane due to its interaction 
with IIb3.   
 
Plasminogen  
Plasminogen has been identified in -granules by proteomic approaches37,38 but the relative 
amounts have not been defined, although it is reportedly released after stimulation39. 
Plasminogen is not detected in megakaryocytes, unless cultured in plasma containing 
plasminogen, indicating that it is endocytosed by the cells.38  There are two forms of 
plasminogen, the native predominant form Glu-plasminogen and the intermediate form Lys-
plasminogen, which is formed by cleavage of the activation peptide from Glu-
plasminogen.40 Glu-plasminogen is cleaved at Arg561-Val562 to form two chain Glu-plasmin 
followed by a further cleavage at the N-terminus to form fully active lys-plasmin.40,41  Lys -
plasminogen has a more open conformation which is more readily activated by plasminogen 
activators.  It is presently unknown whether the -granular pool is Glu- or Lys- plasminogen 
or if it differs from the plasma forms.  
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Inhibitors of fibrinolysis 
A number of fibrinolytic inhibitors exist within platelets and as a result of this platelet-rich 
thrombi are reportedly more resistant to tPA-mediated lysis than erythrocyte-rich 
thrombi.42 The platelet content of thrombi and their resistance to lysis may help to explain 
why recanalization in some stroke patients fails.43  
 
Plasminogen activator inhibitor-1 (PAI-1) 
The serine protease inhibitor, PAI-1, is the principal inhibitor of tPA and urokinase 
plasminogen activator (uPA).  PAI-1 is abundant in -granules (0.67 ng/106 platelets) and is 
released upon platelet activation, accounting for the majority of circulating PAI-1.2 Platelets 
contain PAI-1 mRNA and are capable of de novo synthesis of functionally active PAI in vitro 
which largely remains in an active conformation.44,45 Platelet PAI-1 is functionally less active 
than the plasma PAI-1, 2,46 but accounts for approximately 50 % of total PAI-1 activity due to 
its sheer abundance.2 Arterial thrombi which contain platelet dense regions47 found to 
contain 2-3-fold more PAI-1 than venous thrombi.48,49 
 
Alpha 2 antiplasmin (2AP) 
2AP is the principal inhibitor of plasmin and can be found within -granules.50,51 On 
average there is 62 ng 2AP/ 109platelets which accounts for 0.05 % of the plasma level on 
a volume basis.50 Platelet 2AP is released upon activation50 and stabilizes platelet-rich clots 
against fibrinolysis.52,53 The contribution of the platelet pool of 2AP to thrombus stability 
may be limited, as addition of normal circulating platelet concentrations to 2AP-depleted 
plasma does not stabilize thrombi against lysis.54 Platelet 2AP may potentially play a role in 
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maintaining the structural integrity of the platelet plug by down-regulating lysis during the 
initial stages of thrombus formation, rather than protecting the established thrombus 
against premature lysis. 
 
Thrombin activatable fibrinolytic inhibitor (TAFI) 
TAFI is a pro-carboxypepetidase that can be activated by thrombin, a reaction that is 
accelerated in excess of 1000-fold by thrombomodulin55 or alternatively by plasmin.56  The 
activated carboxypepetidase, TAFIa, removes C-terminal lysine residues from fibrin that has 
been partially degraded reducing the availability of binding sites for tPA and  plasminogen.57 
TAFI is present in platelets at approximately 50 ng/ 109 platelets and is released from -
granules upon activation4 in concentrations sufficient to down-regulate fibrinolysis of 
platelet-rich thrombi.58  Megakaryocytes contain TAFI mRNA and biosynthesis of this protein 
is thought to account for the pool of TAFI residing in granules.4,58     
 
Histidine rich glycoprotein (HRG) 
The plasma glycoprotein HRG plays a role in multiple physiological processes including 
coagulation and fibrinolysis.  HRG is endocytosed by platelets and megakaryocytes59, with 
this pool accounting for 0.14% of the plasma level.60 HRG is released upon platelet 
activation59,60 and directly associates with the membrane of activated platelets.61  
Interestingly, HRG-/- mice exhibit longer tail bleed times, indicative of defective platelet 
activation, increased antithrombin activity, shorter prothrombin times and enhanced 
spontaneous fibrinolysis.62 As HRG is known to bind to fibrinogen63 and is retained on the 
fibrin surface after clot formation64, co-localization with fibrinogen in -granules mean they 
could potentially be released as a complex following stimulation.  HRG also acts as an 
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competitive inhibitor of plasminogen by binding to lysine binding site 1, potentially down-
regulating association of plasminogen and fibrin.65  Conversely, it is reported to tether 
plasminogen to the cell-surface, thereby enhancing the migratory potential of cells.66 
Further work is required the significance of this protein in regulating fibrinolysis.    
 
Platelet C1-inhibitor 
C1-inhibitor is a serpin which inhibits serine proteases of the complement, contact, and 
fibrinolytic systems.  C1-inhibitor is contained in -granules67 and is secreted upon 
activation with a portion (23%) retained on the membrane.3 The platelet pool of C1-inhibitor 
is derived from megakarocyte biosynthesis with platelets containing 62 ng/ 108 platelets 
compared to the relatively high plasma concentration of 290 g/ml.3 C1-inhibitor forms a 
complex with tPA in situations when it is in excess over PAI-1.68-70 A recent report suggests 
that C1-inhibitor is the principal inhibitor of a single-site, Lys300  -> His  mutant  (M5)  form 
of scuPA, which is less vulnerable to non-specific activation to uPA.71 Infusion of C1-inhibitor 
prior to administration of the mutant form of scuPA prevented non-specific activation of 
plasminogen and fibrinogenolysis whilst permitting lysis of partially-degraded fibrin.72    
 
Protease nexin-1 (PN-1) 
Protease nexin-1 (PN-1), also called serpinE2, is a serpin inhibitor with a broad spectrum of 
substrates including thrombin, factor Xa, factor XIa and activated protein C, as well as the 
fibrinolytic proteins plasmin, tPA and uPA (reviewed by73). Interestingly, PN-1 is the closest 
homologue of PAI-173 eluding to a function in regulation of fibrinolysis. It is expressed by 
most blood cells including platelets74,75 where the majority is contained within -granules, 
but a small amount exists on the quiescent platelet membrane.76  The concentrations of PN-
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1 released in the secretome are relatively high (20 nmol/L per 3 x 108 platelets)73 but a pool 
is retained on the activated membrane surface.74  Platelet PN-1 has the capacity to inhibit 
both tPA-mediated fibrinolysis and directly down-regulates plasmin generation and activity 
on fibrin.77  A blocking antibody to PN-1 enhances lysis of platelet-rich clots and PN-1-/- mice 
exhibit accelerated lysis compared to wild-type.77  Indeed, a deficiency in PN-1 significantly 
augments t-PA mediated thrombolysis77 emphasizing its clear inhibitory role in fibrinolysis. 
 
DENSE GRANULES 
Dense granules (or dense bodies) are less abundant than -granules, with only around 6-8 
per platelet, at around 250 nm in size, and are identified in electron micrographs by virtue 
of their electron dense cores.  Dense granules are comprised of cations (Ca2+, Mg2+ K+), 
phosphates (polyphosphate (polyP) and pyrophosphate), bioactive amines (serotonin and 
histamine) and nucleotides (ATP, ADP, UTP, GTP). High concentrations of these constituents 
are achieved by active transport mechanisms which also maintains the granule lumen at a 
pH of around 5.4.  The components of dense granules ,in particular serotonin, ADP, Ca2+ and 
polyP regulate hemostasis, which will be described in more detail below.      
 
Polyphosphate (polyP)  
PolyP is an inorganic phosphate molecule comprising of a repeating units of phosphate 
monomers joined by phosphoanhydride bonds.78 79 79,80 PolyP elicits numerous effects on 
coagulation and fibrinolysis inducing significant augmentation of the clotting process by 
enhancing factor XII (FXII) activation, preventing inhibition of factor Xa (FXa) by tissue factor 
pathway inhibitor (TFPI), and acting as a cofactor for thrombin-mediated activation of factor 
XI (FXI).81 These procoagulant effects have a downstream impact on fibrinolysis by 
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enhancing TAFIa activation due an acceleration of thrombin generation.81  Polymer length is 
an critical determinant of polyP function; longer polymers are significantly more effective in 
activation of FXII.82 PolyP binds to fibrinogen83 and alters the structure of the fibrin network, 
in doing so it attenuates binding of tPA and plasminogen to fibrin, thereby delaying tPA-
mediated fibrinolysis.83 PolyP binds to FXII,80,84 facilitates its autoactivation84 and has been 
shown to augment FXII-driven coagulation.81,85 Despite being classified as a coagulation 
factor, activated FXII (FXIIa) demonstrates weak plasminogen activator activity.86,87 Recently, 
it has been shown that FXIIa can augment tPA-mediated fibrinolysis by generating additional 
plasmin.88 Our recent work has shown that polyP can activate FXII84 and subsequently acts 
as a cofactor in enhancing its plasminogen activator activity which is the first profibrinolytic 
function of polyP to be documented.  
 
CYTOPLASMIC PROTEINS 
Factor XIII (FXIII) 
Activated FXIII (FXIIIa) increases the mechanical stability of clots by forming -(-glutamyl) 
lysyl bonds in fibrin89 through cross-linking the lysine -amino group of one fibrin strand to 
the glutamine -carboxymide group of another.90 FXIII is present in platelets91-93 at high 
concentrations (around 60 fg per platelet)94 and is largely contained within the 
cytoplasm.29,95  Unlike the heterodimer A2B2 form that circulates in plasma, the cellular form 
exists as a homodimer of FXIII-A.29,95 A small pool of the A2B2 form is reported to be 
contained in -granules29,96 which is presumed to be taken up from plasma in association 
with fibrinogen.96  Early studies indicated that FXIII-A is retained in the platelet cytoplasm 
following activation and is not detectable in the secretome.97 FXIII-A does not contain an 
identifiable endoplasmic reticulum (ER) signaling sequence and is excluded from the ER-
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Golgi pathway in nucleated cells.98 However, it has been found to be directed toward the 
plasma membrane in association with Golgi vesicles in monocyte-macrophages.99 Due to the 
lack of ER-leader sequence FXIII-A cannot be targeted to -granules in nascent platelets 
during de novo synthesis in megakaryocytes. This evidence has led to the assumption that 
release of FXIII-A from platelets was improbable and its functions were likely to be 
intracellular and distinct from the role of the plasma FXIII in hemostasis. Plasma FXIII plays 
an essential role in the regulation of fibrinolysis where it cross-links inhibitors of fibrinolysis 
to fibrin, including 2AP100, TAFI101, and PAI-2.102 We have shown that the antifibrinolytic 
function of plasma FXIIIa is mediated by cross-linking 2AP to fibrin103 and in its absence 
thrombi lyse rapidly.104 Platelet FXIII-A was shown to induce high molecular weight -dimer, 
-polymers and 2AP-fibrin cross-links.52,53,105-107 Our work has now shown that platelet 
FXIII-A is externalized on the activated platelet membrane and mediates extracellular fibrin 
cross-linking reactions stabilizing thrombi against fibrinolysis in an 2AP-dependent 
manner.54   
 
Tissue factor pathway inhibitor (TFPI) 
Two alternatively spliced isoforms of TFPI exist in blood: TFPI and TFPIβ.108,109  Platelets 
exclusively express the TFPI isoform which is derived from megakaryocytes and accounts 
for approximately 7-10 % of the total pool of TFPI in whole blood.110,111  At this time, it is 
unknown where TFPI is located within quiescent platelets but evidence suggests it is not 
found in -granules or lysozymes, as it does not co-localize with VWF, fibrinogen, or 
lysosomal-associated membrane protein-1 (LAMP-1).110  TFPI is exposed on the surface of 
platelets following strong stimulation with thrombin or dual agonists via an unknown 
mechanism.110 In addition to platelet surface expression, a soluble form of TFPI is released in 
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response to strong agonist stimulation, allowing accumulation of the inhibitor at sites of 
vascular injury to act directly on tissue factor/factor VIIa complex and attenuate thrombus 
propagation.  TFPI-2, a homologue of TFPI-1, has recently been identified within platelets 
and is of megakaryocytic origin.112 TFPI-2 is released from platelets in response to TRAP-6 
stimulation and strongly attenuates tPA-mediated plasma clot lysis by directly inhibiting 
plasmin.  The levels of TFPI-2 rise steadily during pregnancy potentially indicating an 
antifibrinolytic role for this kunitz inhibitor in control of bleeding during labour.112  
 
FIBRINOLYTIC PROTEINS ON THE MEMBRANE SURFACE 
The activated membrane surface of platelets is well documented in terms of its binding of 
coagulation factors, via Gla-domains and integrin binding to fibrinogen, VWF, and collagen.   
Perhaps less well explored is the ability of the platelet membrane to serve as a binding site 
for fibrinolytic proteins.   
 
Urokinase plasminogen activator (uPA) 
The plasminogen activator uPA is a 54 kDa serine protease found in urine and synthesized 
by fibroblast-like cells, monocytes, macrophages113,114, and epithelial cells.115 The single 
chain form of uPA, scuPA, is activated to two chain uPA by cleavage at Lys158-Ile159.116 
Normal platelets contain a small amount (1.3 ng uPA/109 platelets) of uPA 117 but negligible 
levels are found in megakaryocytes.  Quebec platelet disorder is associated with enhanced 
expression and storage of uPA and manifests as delayed onset of bleeding after injury. 
Increased expression of uPA, develops during differentiation of megakaryocytes from 
hematopoietic progenitors and is linked to a tandem duplication in the PLAU gene.38 The 
limited plasminogen activator concentration in normal platelets may serve a protective 
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function, as Quebec platelet disorder results in intracellular generation of plasmin which is 
associated with degradation of -granule proteins.118  
 
In sharp contrast to the inhibitory effect of platelets on t-PA- and uPA-mediated fibrinolysis 
we and others have shown that scuPA-mediated lysis is dramatically enhanced by platelets. 
5,119 This seems counterintuitive considering the high concentrations of fibrinolytic inhibitors 
in platelets, but is explained by surface-mediated reciprocal activation of plasminogen and 
scuPA on the membrane surface.5  scuPA is present on the membrane of unstimulated 
platelets120, however binding is not accounted for by the known cellular receptor uPAR121, 
as uPAR is not expressed on platelets.  Exogenous scuPA is endocytosed by platelets, by an 
underdetermined mechanism, which may prolong its activity.122  Once formed, cell-bound 
plasmin is protected from inhibition by 2AP, although (sc)uPA is susceptible to inhibition by 
PAI-1 and PAI-2.  An additional mechanism of activation of thrombin-cleaved scuPA by 
platelet cathepsin C has also been described on the surface of thrombin-stimulated 
platelets.123  Despite these lines of evidence locating (sc)uPA on the membrane of quiescent 
and activated platelets, the receptors responsible are still unknown. 
 
Tissue-type plasminogen activator (tPA) 
tPA, a 68 kDa serine protease, is largely produced and secreted by endothelial cells124 
however, small amounts of active tPA have been detected in megakaryocytes.125  tPA is 
secreted as a single-chain form (sctPA) that is cleaved at Arg275-Ile276 to a two-chain form 
(tctPA).  When associated with fibrin, both forms exhibit comparable activity,126 as binding 
of sctPA to fibrin decreases the Km of activation, enhancing plasmin generation and down-
stream fibrinoysis.127 tPA binds to the surface of quiescent platelets potentiating 
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plasminogen activation approximately 8-fold.128,129  Reversible binding of tPA to the 
membrane appears to be by a single-class of saturable, low affinity binding sites that are 
amplified upon thrombin stimulation and partially displaced by plasminogen.129,130 
Receptors for tPA on platelets have not been definitively identified, but annexin II has been 
described as a plasminogen-tPA co-receptor on endothelial cells.131     
 
Platelet-rich regions within clots are associated with densely packed retracted fibrin fibers 
which attenuate tPA binding and decrease lysis front velocity.16,132  Interestingly, a second 
late phase acceleration of fibrinolysis is observed which is attributed to clustering of lysing 
fibers which augments the local concentration of fibrin-bound tPA.132  The relative 
contribution of fibrin versus the cell surface in accelerating local fibrinolysis is an intriguing 
question but one that is difficult to tackle experimentally.  
 
PLATELET SUBPOPULATIONS  
Upon activation of platelets, a number of phenotypically different subpopulations arise 133-
136 which have different functions within the microenvironment of the thrombus. 
Procoagulant platelets express phosphatidlyserine (PS)137, readily binding coagulation 
factors, thereby enhancing thrombin generation and downstream fibrin formation. 
Adherent platelets expose activated IIbβ3, bind fibrin and other platelets thereby 
consolidating the thrombus and protecting against premature degradation.138  
 
Aggregating platelets 
Aggregating platelets are PS-negative with a characteristic spread morphology (Figure 2A).  
They bind fibrinogen via activated IIbβ3 and generate fibrin on their surface.138  
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Aggregating platelets expose FXIII-A in a diffuse pattern over their surface54, whilst 
plasminogen and PAI-1 localize centrally over the granulomere (Figure 3).6 Binding of 
plasminogen is attenuated by blocking IIbβ3 with tirofiban, however it is not dependent on 
the active conformation of the integrin.  This is evidenced by the fact that plasminogen 
accumulates on the surface of aggregating platelets prior to  PAC-1 antibody which binds 
only the active integrin.6  The functional significance of these fibrinolytic proteins in 
aggregating platelets requires further clarification.  However, their importance in thrombus 
architecture and stability is exemplified by addition of abciximab, a IIbβ3 receptor 
antagonist, which significantly accelerates lysis by prohibiting the interaction between 
fibrin(ogen) and platelets.139   
 
PS-exposing platelets 
Upon exposure to a collagen surface or glycoprotein VI ligands, platelets initially form 
pseudopods and lamellipodia before morphing to a characteristic ‘balloon’ shape and 
flipping PS to the activated membrane (Figure 2B).140 PS-exposing platelets, or procoagulant 
platelets, exhibit prolonged increases in cytosolic Ca2+ and support binding of the 
prothrombinase complex. 136,138,141  After the appearance of aggregating platelets, which 
incorporate fibrinogen, further platelets are recruited that subsequently become PS-
positive.138 These platelets allow formation of ‘star-like’ fibrin network which emanates 
from the platelet surface under low shear. This process is dependent on both FXIIIaand 
IIbβ3142, as in their absence fibrin fibers orientate in the direction of flow.143 These 
observations indicate that PS-exposing platelets contribute to the dynamic structure of the 
fibrin network by guiding multi-directional fibrin polymerization and may have downstream 
consequences in terms of modulating fibrinolysis. Platelet FXIII-A and calpain have a role in 
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limiting excessive accumulation of platelets by decreasing adhesion via IIbβ3.134  
Interfering with PS exposure on platelets impairs FXa and thrombin generation thereby 
downregulating thrombus formation in murine models of thrombosis.144,145 These thrombi 
are prone to embolization, exhibit reduced stability and increased susceptibility to lysis   
 
Coated platelets  
‘Coated platelets’ are procoagulant platelets produced by strong dual agonist 
stimulation.133,146,147 Coated platelets retain a ‘coat’ of cross-linked -granule proteins on 
their surface143,146,148 which is reported to develop secondary to PS exposure.149 The protein 
coat consist of procoagulant proteins such as factor V, VWF, and fibrinogen which are 
reportedly cross-linked to the surface in a FXIIIa-dependent manner.  The presence of 
fibrinolytic proteins such as PAI-1, HRG, and plasminogen on coated platelets is less well 
described, but they too could be present within the ‘coat’.  The percentage of coated 
platelet potential in individuals ranges from 15 – 53%.l.147  The full physiological role and 
capacity of coated platelets is not fully understood, however, they are thought to be 
prothrombotic in nature.150-151  Therefore, the ability to target and enhance the 
profibrinolytic potential of this subpopulation may have therapeutic value.   
 
Protruding ‘cap’ on procoagulant platelets 
Procoagulant PS-exposing platelets have been found to possess a protruding ‘cap’ which is 
rich in fibrinogen and thrombospondin.152  We have recently confirmed the presence of 
fibrinogen and demonstrated the localization of FXIII-A54, plasminogen, and PAI-16 in these 
protruding caps (Figure 3).   These ‘caps’ have since been demonstrated to contain 
numerous coagulation factors IXa, Xa/X, Va and VIII.153 Fibrin may act as an anchor for these 
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proteins within the platelet ‘cap’ and could potentially facilitate the transfer of platelet-
derived proteins into the adjoining fibrin network. Indeed activation of platelets with TRAP-
6 rather than thrombin or inhibition of fibrin polymerization with Gly-Pro-Arg-Pro reduced 
exposure of platelet FXIII-A54 and attenuated plasminogen binding within the ‘cap’.6 
However, despite the presence of fibrin(ogen), IIbβ3 appears to be in an inactive 
conformation.  Platelets stimulated with strong dual agonists display secondary inactivation 
of the integrin after occupation with a ligand such as fibrinogen.134,146,154,155 Blocking IIbβ3 
or fibrin polymerization reduces plasminogen binding to PS-exposing platelets6 and 
consistent with this Glanzmann thrombasthenia patients who lack IIbβ3 display reduced 
plasminogen binding.156 
 
These protein rich ‘caps’ on the surface of PS-exposing platelets are not fully understood but 
their collection of fibrinolytic mediators implies a functional role in fibrinolysis. Within a 
developing thrombus, the PS-exposing platelets are visualized as distinct non-aggregating 
platelets that localize in strings at the edges of clots138 and may limit excessive clot 
expansion by curbing association of additional platelets while permitting further generation 
of fibrin. The collection of proteins in these protruding ‘caps’ suggest they may act as a 
delivery service for fibrinolytic proteins into the heart of the thrombus.  
 
THROMBUS ARCHITECTURE, LOCALIZATION OF PLATELETS AND FIBRINOLYTIC PROTEINS 
During thrombus formation a core of densely packed, highly activated platelets forms which 
is enveloped by a shell of loosely packed less activated platelets.157   The rate of solute 
transport within the core of the thrombus is low158 indicating that proteins associated with 
the platelet membrane or within the gap junctions of these tightly packed aggregates will be 
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retained.  These platelets experience strong agonist stimulation evoking prolonged 
intracellular calcium spikes, shape change and rapid degranulation.159 In the shell of the 
thrombus, platelets are less intensely stimulated, displaying only transient increases in 
intracellular calcium with little or no degranulation.159  This is an important concept, as it 
indicates that platelets do not release their intracellular contents into flowing blood, but 
rather into the body of the thrombus where local concentrations of platelet-derived 
proteins are likely to define the hemostatic balance.    
 
Upon thrombin stimulation the copy number of IIb3 on the membrane increases 2-3-fold, 
presumably drawing from the pool within -granules.160  The concurrent sharp rise in 
intracellular Ca2+ induces the active conformation of IIbβ3161 and interaction with 
fibrinogen.9  Thrombin concentrations are elevated within the core of the thrombus 
facilitating further fibrin formation and platelet activation thereby dictating the overall 
structure and its resistance to fibrinolysis.   
 
Plasminogen associates with unstimulated platelets, but following thrombin stimulation 
binding is significantly augmented in a fibrin and IIb3-dependent manner.  6,162,163 An 
array of plasminogen receptors have been identified on different cell types and generally 
involve an interaction of plasminogen with C-terminal lysine residues of membrane-bound 
proteins.164  The plasminogen content of a thrombus dictates its susceptibility to lysis165 and 
is likely related to its ability to be retained on the surface of fibrin and cells.  Our laboratory 
studied the localization of plasminogen in a physiological flow model of thrombus formation 
and lysis.6  Plasminogen accumulated on platelet-associated fibrin, with a smaller pool 
found in direct association with the platelet surface (Figure 4).6   Plasminogen was initially 
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visualized in the ‘core’ of the thrombus in direct association with platelets, but as time 
progressed it was evident at areas distal to the core localizing with fibrin; both fibrin and 
plasminogen accumulation in these areas was blocked by inclusion of hirudin during 
thrombus formation.6  Using this flow model we have shown that both fibrin and cellular 
surfaces are important for retention of plasminogen within thrombi and that its local 
concentration governs the rate of fibrin degradation.   
 
Stimulation of platelets with strong dual agonists, thrombin and convulxin, generates 
measurable quantities of plasmin which is significantly augmented by addition of 
plasminogen activators.6 We have previously shown a relationship between platelet-
associated plasminogen and scuPA5, as described earlier in this review.  Cell-bound uPA 
recognizes and activates both lys-plasminogen and ACA-liganded plasminogen, which has 
an open conformation similar to lys-plasminogen.166 Association of plasminogen with the 
platelet surface induces an open conformation which is more readily cleaved to 
plasmin.5,162,166-169 Platelet-bound plasminogen can also be activated by crosstalk with uPA 
bound to monocytes or endothelial microparticles.166 tPA-mediated plasminogen activation 
is also enhanced by platelets and is thought to arise from an autocatalytic mechanism.168 In 
addition to the surface enhancement of plasminogen activation, the platelet surface acts as 
a reservoir of plasmin that is protected from inhibition by 2AP thereby promoting 
fibrinolysis.170,171   
 
PAI-1 accumulates to high concentrations in platelet-rich thrombi49,165 and its concentration 
directly correlates with their lysability.165,172   PAI-1 is not cross-linked to fibrin like 2AP, but 
associates indirectly via its cofactor, vitronectin173, which also preserves the activity of this 
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labile serpin inhibitor.174,175 Upon release from -granules PAI-1 localizes on platelet-bound 
fibrin thereby increasing the local resistance of this network to fibrinolytic degradation.176  
TAFI is also released from -granules in response to stimulation4,6 and exerts an additional 
antifibrinolytic function to that of the plasma pool.58 Thrombin generation on the platelet 
membrane and concomitant release of TAFI with platelet-derived TM177, may accelerate 
generation of TAFIa in platelet-rich areas. Plasmin activity generated on the surface of 
activated platelets6 may also function in local TAFI activation and indeed our laboratory has 
previously shown that both thrombin/TM and plasmin-mediated TAFI activation regulate 
thrombus lysis.178 TAFIa has also been found to play a significant role in resistance of 
platelet-rich clots to lysis.179 Indeed, dual targeting of PAI-1 and TAFIa using antibody 
approaches has shown to be beneficial and is currently under investigation as novel 
thrombolytic agent for the prevention of ischaemic stroke.180,181 
 
Platelet FXIII-A stabilizes thrombi against fibrinolysis by cross-linking 2AP to fibrin of plasma 
and platelet origin.52,53,105. These extracellular cross-linking reactions are achieved by 
translocation of FXIII-A from the cytoplasm to the outer-leaflet of the stimulated platelet 
membrane. FXIII-A is not detected in the secretome indicating that externalization to the 
membrane is sufficient for the transglutaminase to mediate extracellular cross-linking 
reactions.54 The distribution of FXIII-A on the surface of platelets differed in relation to the 
subpopulation and further work is necessary to determine which of these is important for 
mediating the antifibrinolytic function of FXIII-A.54   
 
FINAL REMARKS AND PERSPECTIVES 
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Traditionally platelets were considered antifibrinolytic in nature, but their ability to harbor 
plasminogen, plasminogen activators, and functional plasmin on their surface mean that 
their role is more complex than initially perceived. Platelets are a heterogeneous population 
of cells that exist in different activated states, reflected in their membrane composition and 
morphology, and as a consequence expose different receptors, molecules and proteins on 
their surface.  Recent advances in defining the subpopulations of platelets and the profile of 
fibrinolytic proteins retained on their membrane surface, or on platelet-bound fibrin, may 
provide clues as to how these platelets function under different conditions.   Whether 
differential packaging and release of pro- and anti-fibrinolytic proteins from -granules 
contributes to regulation of fibrinolysis in different settings remains to be established.  
Time-dependent surface expression of platelet-derived proteins and binding of exogenous 
plasma-derived proteins may impact on the function of these complex cells on fibrinolysis.  
Understanding the function of platelet subpopulations could allow for thrombolytic 
therapies to be tailored to target populations. A recent report showed that thrombolysis 
with scuPA fused to single chain antibody fragments (scFv), which target activated αIIbβ3, 
was dependent on platelet-bound plasminogen.182 The possibility that platelets could serve 
in the rapid delivery of specific pro- or anti-fibrinolytic protein packages provides an exciting 
opportunity to harness their potential therapeutic value.   
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FIGURE LEGENDS 
Figure 1: Cartoon representation of platelet structure.   
A basic schematic of platelet structure indicating several membrane receptors and their 
ligands, including IIb3 and its ligand fibrinogen and the PAR1 and PAR4 receptors with 
their ligand, thrombin. The actin cytoskeleton is attached to the inner leaflet of the platelet 
membrane and joins to the cytoplasmic tails of the IIb3 receptor via clot retraction 
mediators such as talin and vinculin.  Platelets contain a number of intracellular granules 
including -granules which contain a plethora of hemostatic proteins and dense-granules 
which house mediators such as Ca2+, serotonin and polyphosphate. Glycoprotein VI (GPVI), 
IX (GPIX), 1b (GP1b , 1b (GP1b)  protease-activated receptor 1 (PAR1) or 4 (PAR4), 
adenosine diphosphate (ADP), ADP receptors (P2Y1 and P2Y12), von Willebrand factor(vWF) 
and plasminogen activator inhibitor (PAI-1). 
Figure 2: Cartoon representation of fibrinolytic factors bound PS-exposing and PS-negative 
platelet surfaces and platelet-anchored fibrin 
A number of fibrinolytic mediators bind to the activated platelet surface and the 
surrounding fibrin network. This diagram represents the pro- (plasminogen, FXIIa) and anti-
fibrinolytic factors (FXIII-A; PAI-1, C1-Inhibitor) bound to activated spread PS-negative (A) or 
balloon-shaped procoagulant PS-exposing platelet surface (B) and platelet-anchored fibrin 
(blue). Histidine rich glycoprotein (HRG), C1 inhibitor (C1 INH), plasminogen (plgn) and 
polyphosphate (polyP). 
 
Figure 3 – Localization of fibrinolytic proteins in PS-exposing and PS-negative platelets. 
Washed platelets (0.5 x 108/ml) were adhered to a collagen (0.6 g) + thrombin (3 pmol) 
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coated slide and stained using FITC-labeled anti-FXIII-A antibody, FITC-labeled activated 
IIb3 (PAC-1) or anti–PAI-1 DyLight 488-labeled antibody. Alexa-fluor647 Annexin A5 (1/20 
dilution) or Annexin A5–FITC (1/20 dilution) was used to detect phosphatidylserine (PS) 
where indicated. Alternativelly after 40 min incubation, plasminogen-DL633 (0.8 M) or 
fibrinogen-AF647 (16.7 g/ml) were added. Shown are representative images (n = ≥ 3 
experiments) of differential interference contrast (DIC) of FXIII, PAI-1 or PAC-1 expression 
and plasminogen or fibrinogen binding on balloon shaped PS-exposing platelets (left) or 
spread PS-negative platelets (right). Images were obtained with a Zeiss LSM710 confocal 
microscope with a 63 x 1.40 oil immersion objective and were analyzed using Zen 2012 
software. Scale bar = 5 m.   
 
Figure 4 - Plasminogen localization within thrombi. Thrombi were formed by whole blood 
perfusion (1000 s-1) over a collagen/tissue factor-coated surface ± hirudin (3 g/ml). 
Platelets labeled with DiOC6 (0.5 g/ml) or fibrinogen-OG488 (75 g/ml) were included. 
Thrombi were perfused with plasminogen–DL-633 (0.8 M). Confocal z-stacks were 
recorded of labeled thrombi (16-bit images of 1024 3 1024 pixels; 106 3 106 mm; stack 
distance 0.5 mm; 50 slices). Representative images and overlays of plasminogen (blue) and 
platelets (green), or fibrin(ogen) (red) taken from z-stacks at the base (0 mm), center (10 
mm), and top (20 mm) of thrombi before (top panel) or after (bottom panel) visible fibrin 
formation. 
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Table 1 – Summary of fibrinolytic proteins detected in platelets. Unknown parameters are 
indicated by ?. a polyphosphate is an inorganic biomolecule. b the total PN-1 concentration 
within platelets has not been reported but the amount released by 3 x 108 platelets/ml is 
approximately 20 mmol/L.73 Plasminogen activator-1 (PAI-1), alpha2 antiplasmin (2AP), 
thrombin activatable fibrinolysis inhibitor (TAFI), histidine rich glycoprotein (HRG), protease nexin-1 
(PN-1), polyphosphate (polyP), factor XIII-A (FXIII-A), tissue factor pathway inhibitor (TFPI), (single 
chain) urokinase plasminogen activator  (scuPA/uPA) and tissue plasminogen activator (tPA). 
 
 
 
 
Protein 
Concentration 
(ng/109 platelets) 
Primary location Biosynthesis/uptake References 
Fibrinogen 52500 -granules, cytoplasm platelet & megakaryocyte endocytosis 28,183 
Plasminogen ? -granules 
megakaryocytic (platelet?) 
endocytosis 
37,38 
PAI-1 670 -granules platelet biosynthesis 2,44 
2AP 62 -granules ? 50 
TAFI 50 -granules megakaryocyte biosynthesis 4,58 
HRG 371 -granules platelet & megakaryocyte endocytosis 59,60 
C1 inhibitor 620 -granules megakaryocyte biosynthesis 3,67 
PN-1 b -granules megakaryocyte biosynthesis 75,76 
polyPa 755 dense granules - 79 
FXIII-A 60000 cytoplasm megakaryocyte biosynthesis 94 
TFPI 22 
? (not thought to be -
granules or lysozymes) 
megakaryocyte biosynthesis 110,111 
scuPA/uPA 1.3 membrane Plasma derived 117,122 
tPA ? membrane Plasma derived 128,129 
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